Milo Biotechnology is a Cleveland, OH based company developing therapies to increase muscle strength and prevent muscle atrophy. The company’s lead program is a skeletal muscle specific transgene of the protein follistatin. The follistatin 344 transgene is delivered via an adeno-associated virus to achieve long lasting and potent expression in muscle. Milo is currently engaged in three clinical studies for rare muscular dystrophies. Milo Biotechnology’s therapy is based on adeno-associated virus (AAV) delivery of follistatin. AAVs are small, non-pathogenic carriers that can be tailored to deliver sustained administration of follistatin via a single dose.
Employees: 11-50
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Rev1 Ventu... | rev1ventur... |
Mentions in press and media 4
| Date | Title | Description |
| 22.09.2016 | Milo Biotechnology Raises Funding from JumpStart and Rev1 Ventures | Milo Biotechnology, a Cleveland, Ohio-based clinical stage company developing therapies to strengthen muscle of patients with neuromuscular diseases, raised a funding round of undisclosed amount. Backers included JumpStart’s Evergreen Fund ... |
| 26.02.2013 | Muscular dystrophy startup secures SBIR grant to continue developing myostatin inhibitor | This approach to treating muscular dystrophy isn’t new, but thus far pharmaceutical companies haven’t had success with it. Wyeth Pharmaceuticals quietly halted the development of its myostatin inhibitor in 2008 after the showed no statistic... |
| 16.02.2012 | Milo Biotechnology Raises $250K Funding from JumpStart | Milo Biotechnology, a Cleveland, OH-based a clinical stage startup developing a therapy to improve the quality of life of muscular dystrophy patients, has raised $250k in funding from JumpStart. Founded by CEO Al Hawkins and Brian Kaspar, P... |
| - | Muscular dystrophy startup secures SBIR grant to continue developing myostatin inhibitor | With a new $300,000 Phase I SBIR grant from the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, biotech startup Milo Biotechnology will march forward with development and testing of its follistatin therapy for m... |